科恩-斯蒂尔斯金融(CNS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CNS 科恩-斯蒂尔斯金融

盘后交易 07-15 18:11:42 EDT

74.30

-2.76

-3.58%

盘后74.30

+0.000.00%

16:04 EDT

最高77.32	最低73.94	成交量20.76万
今开77.05	昨收77.06	日振幅4.38%
总市值37.88亿	流通市值20.48亿	总股本5,098万
成交额1,548万	换手率0.75%	流通股本2,756万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CNS","market":"US","secType":"STK","nameCN":"科恩-斯蒂尔斯金融","latestPrice":74.3,"timestamp":1752609600000,"preClose":77.06,"halted":0,"volume":207563,"hourTrading":{"tag":"盘后","latestPrice":74.3,"preClose":74.3,"latestTime":"16:04 EDT","volume":7707,"amount":572630.1,"timestamp":1752609854900},"delay":0,"floatShares":27564669,"shares":50979157,"eps":3.05822,"marketStatus":"盘后交易","change":-2.76,"latestTime":"07-15 18:11:42 EDT","open":77.05,"high":77.315,"low":73.94,"amount":15482538.258185,"amplitude":0.043797,"askPrice":118.68,"askSize":200,"bidPrice":29.68,"bidSize":200,"shortable":3,"etf":0,"ttmEps":3.05822,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1752624000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1092369600000,"exchange":"NYSE","adjPreClose":77.06,"dividendRate":0.032167,"postHourTrading":{"tag":"盘后","latestPrice":74.3,"preClose":74.3,"latestTime":"16:04 EDT","volume":7707,"amount":572630.1,"timestamp":1752609854900},"volumeRatio":1.022757,"impliedVol":0.2672,"impliedVolPercentile":0.528},"requestUrl":"/m/hq/s/CNS","defaultTab":"news","newsList":[{"id":"2551195727","title":"Silo Pharma, Inc.盘中异动 临近午盘急速跳水5.88%报0.560美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551195727","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551195727?lang=zh_cn&edition=full","pubTime":"2025-07-15 23:47","pubTimestamp":1752594466,"startTime":"0","endTime":"0","summary":"北京时间2025年07月15日23时47分，Silo Pharma, Inc.股票出现异动，股价急速下跌5.88%。Silo Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.32%。Silo Pharma, Inc.公司简介：SILO Pharma Inc是一家处于发展阶段的生物制药公司，开发新型疗法，用于治疗治疗不足的疾病，包括压力引起的精神疾病、慢性疼痛疾病和中枢神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715234746a44cc1ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715234746a44cc1ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4202","BK4135","CNS","SILO"],"gpt_icon":0},{"id":"2551872861","title":"Silo Pharma, Inc.盘中异动 股价大跌5.77%报0.550美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551872861","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551872861?lang=zh_cn&edition=full","pubTime":"2025-07-14 21:37","pubTimestamp":1752500253,"startTime":"0","endTime":"0","summary":"北京时间2025年07月14日21时37分，Silo Pharma, Inc.股票出现波动，股价快速下跌5.77%。Silo Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。Silo Pharma, Inc.公司简介：SILO Pharma Inc是一家处于发展阶段的生物制药公司，开发新型疗法，用于治疗治疗不足的疾病，包括压力引起的精神疾病、慢性疼痛疾病和中枢神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071421373497a5be08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071421373497a5be08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4202","BK4135","CNS","SILO"],"gpt_icon":0},{"id":"2551912064","title":"全球首次：小胶质细胞替换治疗取得突破，成功阻断致命脑疾病进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2551912064","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551912064?lang=zh_cn&edition=full","pubTime":"2025-07-13 08:40","pubTimestamp":1752367200,"startTime":"0","endTime":"0","summary":"小胶质细胞功能障碍会导致多种中枢神经系统疾病。▲全球首次实现的小胶质细胞替换策略研究首次完成了模拟人类 ALSP 病理的关键动物模型构建。这也是首次在人类患者中系统性验证小胶质细胞替换策略的临床可行性与长期疗效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2025-07-13/doc-inffhtrq8792504.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PET","CNS","BK4139","BK4020","BK4135","BK4192","CAMP"],"gpt_icon":0},{"id":"2550957500","title":"Silo Pharma, Inc.盘中异动 大幅上涨5.01%报0.660美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550957500","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550957500?lang=zh_cn&edition=full","pubTime":"2025-07-11 23:33","pubTimestamp":1752247986,"startTime":"0","endTime":"0","summary":"北京时间2025年07月11日23时33分，Silo Pharma, Inc.股票出现波动，股价急速拉升5.01%。截至发稿，该股报0.660美元/股，成交量23.5448万股，换手率3.27%，振幅7.32%。Silo Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.79%。Silo Pharma, Inc.公司简介：SILO Pharma Inc是一家处于发展阶段的生物制药公司，开发新型疗法，用于治疗治疗不足的疾病，包括压力引起的精神疾病、慢性疼痛疾病和中枢神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711233307a6a428a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711233307a6a428a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SILO","BK4135","CNS","BK4139","BK4202"],"gpt_icon":0},{"id":"2547201881","title":"科恩-斯蒂尔斯金融盘中异动 快速跳水5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2547201881","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547201881?lang=zh_cn&edition=full","pubTime":"2025-06-30 22:10","pubTimestamp":1751292621,"startTime":"0","endTime":"0","summary":"北京时间2025年06月30日22时10分，科恩-斯蒂尔斯金融股票出现波动，股价急速下挫5.02%。科恩-斯蒂尔斯金融股票所在的资产管理行业中，整体涨幅为0.06%。科恩-斯蒂尔斯金融公司简介：科恩-斯蒂尔斯金融有限公司是一家专注于房地产证券的利基资产管理公司。科恩-斯蒂尔斯金融有限公司还管理专门的投资组合 优先证券、公用事业股票和其他高收益产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630221022a4c6d5df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630221022a4c6d5df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4135","CNS"],"gpt_icon":0},{"id":"2545238463","title":"CNS Pharmaceuticals宣布举办虚拟投资者KOL连线环节，讨论多形性胶质母细胞瘤（GBM）及主要候选产品TPI 287CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme GBM and Lead Product Candidate TPI 287","url":"https://stock-news.laohu8.com/highlight/detail?id=2545238463","media":"动脉网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545238463?lang=zh_cn&edition=full","pubTime":"2025-06-24 21:25","pubTimestamp":1750771500,"startTime":"0","endTime":"0","summary":"The Virtual Investor KOL Connect segment featuring CNS Pharma is now available虚拟投资者KOL Connect关于CNS Pharma的片段现已上线。About CNS Pharmaceuticals, Inc.关于CNS制药公司CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.CNS Pharmaceuticals是一家临床阶段的制药公司，正在开发一系列用于治疗原发性和转移性脑及中枢神经系统癌症的抗癌候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624212913978ce7db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624212913978ce7db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CNSP","BK4135","KOL","CNS","BK4007"],"gpt_icon":0},{"id":"2544958965","title":"7.95亿美元被收购！Sage另觅他主，Biogen“抄底”失败","url":"https://stock-news.laohu8.com/highlight/detail?id=2544958965","media":"药时代","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544958965?lang=zh_cn&edition=full","pubTime":"2025-06-17 14:53","pubTimestamp":1750143202,"startTime":"0","endTime":"0","summary":"Biogen“抄底”Sage早在2020年，Biogen便以约6.5亿美元投资Sage，获得其10%股权。2025年1月，Biogen以不足5亿美元的价格向sage提出收购要约。董事会很快谈妥，一周后将向特拉华州法院对Biogen提起诉讼，要求法院颁布禁令，阻止交易达成。虽然Biogen的报价相比前收盘价溢价30%。2025年初Sage被Biogen看中，又花落Supernus，在这场收购博弈中坚持了五个月，Sage成功将收购价提升了近3亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617145655a70db407&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617145655a70db407&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1551013425.SGD","LU1674673691.USD","BK4530","BK4533","LU0868494708.USD","IE00BWXC8680.SGD","BK4083","BK4135","BK4161","BK4550","IE00BSNM7G36.USD","LU1093756325.SGD","LU1914381329.SGD","LU2756315664.SGD","LU1035775433.USD","LU0689472784.USD","LU0823411888.USD","LU1496350171.SGD","HD","LU1778281490.HKD","BK4139","LU0889565916.HKD","LU0820562030.AUD","LU0354030511.USD","LU0109394709.USD","LU1674673428.USD","LU0320765992.SGD","BK4504","PPD","LU0823434583.USD","LU1162221912.USD","LU1093756168.USD","BK4534","LU0820561818.USD","IE00B894F039.SGD","CVR","BIIB","LU0320765646.SGD","BK4561","LU1551013342.USD","BK4121","LU0354030438.USD","BK4532","IE00B19Z9Z06.USD","LU0943347566.SGD","IE00BKVL7J92.USD","LU0820561909.HKD","CNS","BK4566","LU1989772840.SGD"],"gpt_icon":0},{"id":"2542595338","title":"葆元医药母公司Nuvation Bio宣布ROS1抑制剂己二酸他雷替尼获FDA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2542595338","media":"医药时间","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542595338?lang=zh_cn&edition=full","pubTime":"2025-06-12 16:16","pubTimestamp":1749716169,"startTime":"0","endTime":"0","summary":"中国大陆地区商品名为达伯乐，在大中华区由Nuvation Bio的全资子公司葆元医药许可信达生物制药集团负责商业化运营。据估计，约2%的NSCLC患者携带ROS1阳性基因。关于Nuvation Bio和葆元医药Nuvation Bio是一家商业化阶段的全球性抗肿瘤生物制药公司，专注于攻克癌症治疗领域重大难题，进而对患者的生活产生深远的积极影响。葆元医药坐落于浙江省杭州市钱塘区中国医药港，在被Nuvation Bio于2024年4月收购后，成为Nuvation Bio的全资子公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612161826a704d4f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612161826a704d4f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4212","CNS","BK4183","BK4135","BK4211","DDC","PFS","BK4007","NUVB","ODD","IE0009354923.USD","BK4195"],"gpt_icon":0},{"id":"2542655397","title":"新股消息 | 国产吸入药物龙头长风药业闯关港交所 CF017放量驱动业绩高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2542655397","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542655397?lang=zh_cn&edition=full","pubTime":"2025-06-12 06:45","pubTimestamp":1749681902,"startTime":"0","endTime":"0","summary":"招股书显示，长风药业主要专注于吸入技术及吸入药物的研发、生产及商业化，专注于治疗呼吸系统疾病。CF017，即治疗支气管哮喘的吸入用布地奈德混悬液，为长风药业的首个获批产品。2021年5月获批后，CF017迅速纳入中国集中采购 计划，并实现了市场增长。根据弗若斯特沙利文的资料，于2024年，按销量计，CF017占2024年中国布地奈德吸入药物市场约16%。自2021年5月获批以来，公司的市场推广体系使CF017成功覆盖了中国超过10000家医疗机构。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1304201.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4135","CNS"],"gpt_icon":0},{"id":"2540033689","title":"Silo Pharma, Inc.6月3日成交额为15.80万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540033689","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540033689?lang=zh_cn&edition=full","pubTime":"2025-06-04 12:34","pubTimestamp":1749011662,"startTime":"0","endTime":"0","summary":"美东时间2025年6月3日，Silo Pharma, Inc.成交额为15.80万美元，成交额较昨日增加50.11%，当日成交量为33.53万股。Silo Pharma, Inc.于2025年6月3日涨8.97%，报0.496美元，该股过去5个交易日涨11.42%，年初至今跌44.29%，过去60日跌61.86%。它专注于开发传统疗法和迷幻疗法的新配方和药物输送系统。公司的主导项目SPC-15是一种针对PTSD 和压力引起的焦虑症的鼻内治疗。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604123428a49948db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604123428a49948db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4202","SILO","CNS","BK4135","BK4139"],"gpt_icon":0},{"id":"2540495257","title":"Silo Pharma, Inc.6月2日成交额为10.52万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540495257","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540495257?lang=zh_cn&edition=full","pubTime":"2025-06-03 12:27","pubTimestamp":1748924850,"startTime":"0","endTime":"0","summary":"美东时间2025年6月2日，Silo Pharma, Inc.成交额为10.52万美元，成交额较昨日增加38.86%，当日成交量为23.32万股。Silo Pharma, Inc.于2025年6月2日涨2.39%，报0.455美元，该股过去5个交易日涨6.06%，年初至今跌48.88%，过去60日跌65.27%。它专注于开发传统疗法和迷幻疗法的新配方和药物输送系统。公司的主导项目SPC-15是一种针对PTSD 和压力引起的焦虑症的鼻内治疗。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603122738a497a390&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603122738a497a390&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4135","BK4139","SILO","CNS","BK4202"],"gpt_icon":0},{"id":"2539214922","title":"Silo Pharma, Inc.5月29日成交额为9.16万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2539214922","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539214922?lang=zh_cn&edition=full","pubTime":"2025-05-30 12:26","pubTimestamp":1748579186,"startTime":"0","endTime":"0","summary":"美东时间2025年5月29日，Silo Pharma, Inc.成交额为9.16万美元，成交额较昨日减少23.15%，当日成交量为19.46万股。Silo Pharma, Inc.于2025年5月29日涨2.88%，报0.472美元，该股过去5个交易日涨5.87%，年初至今跌46.94%，过去60日跌62.22%。它专注于开发传统疗法和迷幻疗法的新配方和药物输送系统。公司的主导项目SPC-15是一种针对PTSD 和压力引起的焦虑症的鼻内治疗。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530122634a4923b85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530122634a4923b85&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SILO","BK4135","CNS","BK4202"],"gpt_icon":0},{"id":"2539210350","title":"再砸10亿美金，Biogen进军CNS研发黑洞","url":"https://stock-news.laohu8.com/highlight/detail?id=2539210350","media":"药时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539210350?lang=zh_cn&edition=full","pubTime":"2025-05-30 12:22","pubTimestamp":1748578925,"startTime":"0","endTime":"0","summary":"Biogen则将负责IND赋能研究和全球临床开发，以及任何监管提交和所有与商业化相关的活动。2025年4月2日，Biogen在CNS小核酸疗法领域传来了喜讯。今年年初，Biogen宣布将以总估值4.42亿美元收购神经科学治疗公司Sage Therapeutics但被制止。此次收购失败，Biogen与Sage的爱恨纠葛还需观望一下。2023年7月28日，Biogen用73亿美元收购Reata，充实神经系统研发管线。今年3月3日，CNS研发药企经历“黑色星期一”。Biohaven、Neumora、Lexicon三家药企同日宣布临床失败或调整。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530135222a6f2d164&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530135222a6f2d164&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z9P08.USD","LU0234570918.USD","IE00B19Z9Z06.USD","BK4532","IE00B894F039.SGD","CNS","LU0109394709.USD","LU0320765992.SGD","BK4533","BK4588","BK4139","BK4135","BK4585","BIIB","LU0889565916.HKD"],"gpt_icon":0},{"id":"2538448273","title":"Silo Pharma, Inc.5月27日成交额为31.17万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2538448273","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538448273?lang=zh_cn&edition=full","pubTime":"2025-05-28 12:27","pubTimestamp":1748406440,"startTime":"0","endTime":"0","summary":"美东时间2025年5月27日，Silo Pharma, Inc.成交额为31.17万美元，成交额较昨日增加326.56%，当日成交量为70.18万股。Silo Pharma, Inc.于2025年5月27日涨3.75%，报0.445美元，该股过去5个交易日跌11.71%，年初至今跌50.0%，过去60日跌67.28%。它专注于开发传统疗法和迷幻疗法的新配方和药物输送系统。公司的主导项目SPC-15是一种针对PTSD 和压力引起的焦虑症的鼻内治疗。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528122724a48f3a6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528122724a48f3a6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SILO","BK4139","BK4135","BK4202","CNS"],"gpt_icon":0},{"id":"2538485759","title":"多款罕见病药物国内获批 “小众药物”如何实现更大可及性？","url":"https://stock-news.laohu8.com/highlight/detail?id=2538485759","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538485759?lang=zh_cn&edition=full","pubTime":"2025-05-27 07:31","pubTimestamp":1748302308,"startTime":"0","endTime":"0","summary":"越来越多的罕见病在国内有了新的治疗选择。5月24日，跨国药企优时比（UCB）宣布，自研生物制剂罗泽利昔珠单抗注射液（商品名：优迪革）正式实现商业化上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505273414936220.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505273414936220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2065731478.USD","CNS","MG","UCB","BK4123","IE00B19Z4B17.USD","BK4135","RCC","IE00B7SZL793.SGD","IE0031619046.USD","CRS","IE00B66KJ199.SGD","BK4211","BK4006"],"gpt_icon":0},{"id":"2537942875","title":"Silo Pharma, Inc.盘中异动 早盘大幅下跌5.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537942875","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537942875?lang=zh_cn&edition=full","pubTime":"2025-05-22 21:32","pubTimestamp":1747920763,"startTime":"0","endTime":"0","summary":"北京时间2025年05月22日21时32分，Silo Pharma, Inc.股票出现异动，股价急速下挫5.81%。Silo Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.10%。Silo Pharma, Inc.公司简介：SILO Pharma Inc是一家处于发展阶段的生物制药公司，开发新型疗法，用于治疗治疗不足的疾病，包括压力引起的精神疾病、慢性疼痛疾病和中枢神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522213245a6e8f1c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522213245a6e8f1c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4135","BK4139","SILO","BK4202","CNS"],"gpt_icon":0},{"id":"2537936063","title":"Silo Pharma, Inc.盘中异动 早盘快速下挫5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537936063","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537936063?lang=zh_cn&edition=full","pubTime":"2025-05-21 21:32","pubTimestamp":1747834339,"startTime":"0","endTime":"0","summary":"北京时间2025年05月21日21时32分，Silo Pharma, Inc.股票出现波动，股价快速下跌5.55%。Silo Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。Silo Pharma, Inc.公司简介：SILO Pharma Inc是一家处于发展阶段的生物制药公司，开发新型疗法，用于治疗治疗不足的疾病，包括压力引起的精神疾病、慢性疼痛疾病和中枢神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505212132199760d9c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505212132199760d9c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SILO","BK4135","CNS","BK4139","BK4202"],"gpt_icon":0},{"id":"2535392370","title":"CNS Pharmaceuticals(CNSP.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-1.58美元，前值为-1020.48美元，预期值为-6.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2535392370","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535392370?lang=zh_cn&edition=full","pubTime":"2025-05-16 20:22","pubTimestamp":1747398160,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals(CNSP.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-1.58美元，前值为-1020.48美元，预期值为-6.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/16202250462160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CNSP","CNS"],"gpt_icon":0},{"id":"2535829894","title":"Silo Pharma, Inc.股价重挫41.08% 市值跌90.75万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535829894","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535829894?lang=zh_cn&edition=full","pubTime":"2025-05-15 21:33","pubTimestamp":1747316015,"startTime":"0","endTime":"0","summary":"北京时间2025年05月15日21时33分，Silo Pharma, Inc.股票出现异动，股价急速下挫41.08%。Silo Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。Silo Pharma, Inc.公司简介：SILO Pharma Inc是一家处于发展阶段的生物制药公司，开发新型疗法，用于治疗治疗不足的疾病，包括压力引起的精神疾病、慢性疼痛疾病和中枢神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515213336a47fa6c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515213336a47fa6c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CNS","BK4202","BK4135","BK4139","SILO"],"gpt_icon":0},{"id":"2535020924","title":"Silo Pharma, Inc.股价重挫10.00% 市值跌44.4万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535020924","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535020924?lang=zh_cn&edition=full","pubTime":"2025-05-14 21:30","pubTimestamp":1747229425,"startTime":"0","endTime":"0","summary":"北京时间2025年05月14日21时30分，Silo Pharma, Inc.股票出现异动，股价快速下跌10.00%。Silo Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Silo Pharma, Inc.公司简介：SILO Pharma Inc是一家处于发展阶段的生物制药公司，开发新型疗法，用于治疗治疗不足的疾病，包括压力引起的精神疾病、慢性疼痛疾病和中枢神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051421302594f6c751&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051421302594f6c751&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CNS","BK4135","BK4139","BK4202","SILO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cohenandsteers.com","stockEarnings":[{"period":"1week","weight":0.0075},{"period":"1month","weight":0.0184},{"period":"3month","weight":0.0316},{"period":"6month","weight":-0.1125},{"period":"1year","weight":0.0151},{"period":"ytd","weight":-0.1655}],"compareEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":0.0466},{"period":"3month","weight":0.1622},{"period":"6month","weight":0.054},{"period":"1year","weight":0.1158},{"period":"ytd","weight":0.0661}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cohen & Steers, Inc.于2004年3月17日组织成为一家特拉华州公司。Cohen & Steers, Inc.是一家全球领先的专注于全球房地产证券，全球上市基础建设，实物资产，大市值股票和推荐证券的投资管理公司。该公司同时还为投资者管理投资策略例如对房地产证券投资组合以及私人房地产管理可选的投资策略。公司服务于全世界的机构和个人投资者。公司的收益主要来自接收于开放和封闭互助基金的投资顾问，行政管理，分销以及服务资费以及接收于机构账户的投资顾问资费。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.017423},{"month":2,"riseRate":0.47619,"avgChangeRate":-0.003477},{"month":3,"riseRate":0.714286,"avgChangeRate":0.026775},{"month":4,"riseRate":0.666667,"avgChangeRate":0.052556},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.003122},{"month":6,"riseRate":0.571429,"avgChangeRate":-0.003319},{"month":7,"riseRate":0.666667,"avgChangeRate":0.032117},{"month":8,"riseRate":0.5,"avgChangeRate":0.008566},{"month":9,"riseRate":0.47619,"avgChangeRate":-0.006664},{"month":10,"riseRate":0.52381,"avgChangeRate":-0.006937},{"month":11,"riseRate":0.666667,"avgChangeRate":0.012914},{"month":12,"riseRate":0.52381,"avgChangeRate":0.017125}],"exchange":"NYSE","name":"科恩-斯蒂尔斯金融","nameEN":"Cohen & Steers"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科恩-斯蒂尔斯金融(CNS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科恩-斯蒂尔斯金融(CNS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科恩-斯蒂尔斯金融,CNS,科恩-斯蒂尔斯金融股票,科恩-斯蒂尔斯金融股票老虎,科恩-斯蒂尔斯金融股票老虎国际,科恩-斯蒂尔斯金融行情,科恩-斯蒂尔斯金融股票行情,科恩-斯蒂尔斯金融股价,科恩-斯蒂尔斯金融股市,科恩-斯蒂尔斯金融股票价格,科恩-斯蒂尔斯金融股票交易,科恩-斯蒂尔斯金融股票购买,科恩-斯蒂尔斯金融股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科恩-斯蒂尔斯金融(CNS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科恩-斯蒂尔斯金融(CNS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}